NinthBio

Executive Summary

NinthBio offers a novel DNA synthesis platform that leverages its proprietary Homology Path technology to design DNA populations from the fewest possible oligos, enabling cost reductions of up to 90% compared to traditional synthesis services. Founded in 2018 and based in San Diego, the company targets molecular biology labs seeking affordable, in-house DNA synthesis for applications such as affinity maturation and protein engineering. By simplifying assembly through a single PCR reaction, NinthBio aims to democratize DNA synthesis, reducing reliance on external providers and accelerating research workflows. Although still private with no disclosed funding, the company's technology addresses a critical bottleneck in synthetic biology, positioning it for potential disruption in the genomics tools market.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round65% success
• Q4 2026Strategic Partnership with a Major Biotech or Pharma Company50% success
• Q3 2026Launch of Enhanced Homology Path Synthesis Platform70% success